Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest gets small-molecule pain candidates from Grunenthal; GRT6005/cebranopadol part ended

Executive Summary

In their second partnership, Grunenthal GMBH (mid-sized European drug company focused on pain management) has licensed Forest Laboratories Inc. exclusive US and Canadian rights to its pain compounds GRT6005 (cebranopadol) and GRT6006 (lexanopadol). Forest also received a European co-promotion option.

Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies